AKT1 and hepatocellular carcinoma: PI3K/AKT signaling is activated in 30%–50% of patients with HCC, and upregulation of phosphorylated AKT (p-AKT) is associated with poor survival and tumor vascular invasion in patients with HCC (172) (Table 1).